JP2002512206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002512206A5 JP2002512206A5 JP2000544366A JP2000544366A JP2002512206A5 JP 2002512206 A5 JP2002512206 A5 JP 2002512206A5 JP 2000544366 A JP2000544366 A JP 2000544366A JP 2000544366 A JP2000544366 A JP 2000544366A JP 2002512206 A5 JP2002512206 A5 JP 2002512206A5
- Authority
- JP
- Japan
- Prior art keywords
- combination preparation
- preparation according
- substance
- combination
- gas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002360 preparation method Methods 0.000 description 24
- 239000000126 substance Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000007789 gas Substances 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 5
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 108010028921 Lipopeptides Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229960004692 perflenapent Drugs 0.000 description 2
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 2
- 229960000909 sulfur hexafluoride Drugs 0.000 description 2
- 238000012285 ultrasound imaging Methods 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- BCNXQFASJTYKDJ-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5-nonafluoro-5-(trifluoromethyl)cyclopentane Chemical compound FC(F)(F)C1(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F BCNXQFASJTYKDJ-UHFFFAOYSA-N 0.000 description 1
- TXGPGHBYAPBDAG-UHFFFAOYSA-N 1,1,2,2,3,3-hexafluoro-4,4-bis(trifluoromethyl)cyclobutane Chemical compound FC(F)(F)C1(C(F)(F)F)C(F)(F)C(F)(F)C1(F)F TXGPGHBYAPBDAG-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- ABQLAMJAQZFPJI-UHFFFAOYSA-N 3-heptyloxolan-2-one Chemical compound CCCCCCCC1CCOC1=O ABQLAMJAQZFPJI-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- -1 fatty alcohol ester Chemical class 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 229960004624 perflexane Drugs 0.000 description 1
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 1
- 229950003332 perflubutane Drugs 0.000 description 1
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9808599.6A GB9808599D0 (en) | 1998-04-22 | 1998-04-22 | Improvements in or realting to contrast agents |
| GB9808599.6 | 1998-04-22 | ||
| PCT/GB1999/001221 WO1999053963A1 (en) | 1998-04-22 | 1999-04-22 | Improvements in or relating to contrast agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002512206A JP2002512206A (ja) | 2002-04-23 |
| JP2002512206A5 true JP2002512206A5 (https=) | 2006-06-15 |
Family
ID=10830802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000544366A Abandoned JP2002512206A (ja) | 1998-04-22 | 1999-04-22 | 改良された造影剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040146462A1 (https=) |
| EP (1) | EP1073473B1 (https=) |
| JP (1) | JP2002512206A (https=) |
| KR (1) | KR20010042915A (https=) |
| CN (1) | CN1306442A (https=) |
| AT (1) | ATE375806T1 (https=) |
| AU (1) | AU3617299A (https=) |
| BR (1) | BR9909822A (https=) |
| CA (1) | CA2329175A1 (https=) |
| DE (1) | DE69937341D1 (https=) |
| GB (1) | GB9808599D0 (https=) |
| HU (1) | HUP0102878A3 (https=) |
| IL (1) | IL139147A0 (https=) |
| NO (1) | NO20005250L (https=) |
| PL (1) | PL343464A1 (https=) |
| WO (1) | WO1999053963A1 (https=) |
| ZA (1) | ZA200005789B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804162A (en) * | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
| DE10119522A1 (de) * | 2001-04-20 | 2002-12-05 | Innovacell Biotechnologie Gmbh | Herstellung und Anwendung einer Suspensionszusammensetzung mit einem Ultraschall-Kontrastmittel |
| KR101280760B1 (ko) | 2002-11-29 | 2013-07-05 | 지이 헬스케어 에이에스 | 초음파 조영 물질 |
| US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
| JP4670083B2 (ja) | 2003-02-04 | 2011-04-13 | ブラッコ・シュイス・ソシエテ・アノニム | 超音波造影剤およびその製造方法 |
| JP2007515471A (ja) * | 2003-12-22 | 2007-06-14 | ブラッコ・リサーチ・ソシエテ・アノニム | 造影イメージング用の活性成分を有する気体封入マイクロベシクルのアセンブリー |
| CN100563718C (zh) * | 2003-12-22 | 2009-12-02 | 伯拉考开发股份有限公司 | 用于反差成像的充气微囊组件 |
| US9248204B2 (en) | 2004-08-18 | 2016-02-02 | Bracco Suisse S.A. | Gas-filled microvesicles composition for contrast imaging |
| US8153435B1 (en) | 2005-03-30 | 2012-04-10 | Tracer Detection Technology Corp. | Methods and articles for identifying objects using encapsulated perfluorocarbon tracers |
| CN100453050C (zh) * | 2005-09-21 | 2009-01-21 | 北京市肿瘤防治研究所 | 提高超声造影图像分辨力的方法和超声造影成像仪 |
| US20080255266A1 (en) * | 2007-04-10 | 2008-10-16 | Gc Corporation | Dental paste composition having x-ray imaging property |
| JP4279328B2 (ja) * | 2007-05-07 | 2009-06-17 | 株式会社日立製作所 | 超音波撮像システム |
| WO2009097277A1 (en) * | 2008-02-01 | 2009-08-06 | Trustees Of Boston University | Cationic contrast agents and methods of use thereof |
| AU2009241762B2 (en) * | 2008-05-02 | 2015-07-16 | Celsense Inc. | Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications |
| EP2470287A4 (en) | 2009-08-28 | 2015-01-21 | Univ Columbia | SYSTEMS, METHODS AND DEVICES FOR PRODUCING GAS-FILLED MICROBUBBLES |
| DE102011005444A1 (de) * | 2011-03-11 | 2012-09-13 | Innora Gmbh | Festes, negatives Röntgenkontrastmittel zur Darstellung des Gastrointestinaltraktes |
| HUE060034T2 (hu) * | 2013-09-27 | 2023-01-28 | Exact Therapeutics As | Ultrahanggal közvetített hatóanyag leadás |
| AP2016009276A0 (en) | 2013-12-19 | 2016-06-30 | Bayer Pharma AG | Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists |
| CN110913769A (zh) * | 2017-07-09 | 2020-03-24 | 利兰斯坦福初级大学董事会 | 利用频谱合成来减少斑点的超声成像 |
| EP3678712A4 (en) * | 2017-09-07 | 2021-06-02 | Imbiotechnologies Ltd. | EMBOLIC AGENTS SENSITIVE TO SOUND |
| CN108586300B (zh) * | 2018-03-28 | 2020-03-17 | 成都福柯斯医药技术有限公司 | 一种s-碘化丁酰硫代胆碱的合成方法 |
| CN114760989A (zh) | 2019-10-25 | 2022-07-15 | 精准医疗股份有限公司 | 胰腺癌的治疗 |
| GB2595513B (en) | 2020-05-29 | 2023-03-29 | Act Therapeutics Ltd | Treatment of infections |
| US11801058B2 (en) * | 2021-03-04 | 2023-10-31 | Accumedical Beijing Ltd. | Liquid embolic compositions |
| GB2605422B (en) | 2021-03-31 | 2025-04-30 | Act Therapeutics Ltd | Treatment of the central nervous system |
| GB2629999B (en) | 2021-04-21 | 2025-03-26 | Act Therapeutics Ltd | Enhancement of treatment with immunotherapeutic agents |
| CN113598820B (zh) * | 2021-08-18 | 2025-09-23 | 南京超微影医疗科技有限公司 | 超声成像方法及装置 |
| EP4261786A1 (en) * | 2022-03-28 | 2023-10-18 | Tata Consultancy Services Limited | Methods and system for low dose x ray computed tomography perfusion imaging |
| NO20221187A1 (en) | 2022-11-04 | 2024-05-06 | Exact Therapeutics As | Method and system for calculating a point estimate of an ultrasound dose |
| CN116271187B (zh) * | 2023-03-21 | 2025-07-04 | 湖北科技学院 | 双模态显影温敏Pickering乳液介入栓塞材料及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5228446A (en) * | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
| US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
| US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
| EP1550464A1 (en) * | 1993-07-30 | 2005-07-06 | IMCOR Pharmaceutical Co. | Stabilized microbubble composition for ultrasound |
| NO940711D0 (no) * | 1994-03-01 | 1994-03-01 | Nycomed Imaging As | Preparation of gas-filled microcapsules and contrasts agents for diagnostic imaging |
| US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
| TR199901544T2 (xx) * | 1996-10-21 | 1999-09-21 | Nycomed Imaging As | Kontrast ajanlar�ndaki veya kontrast ajanlar�yla ilgili geli�meler. |
| EP0963209A2 (en) * | 1996-10-28 | 1999-12-15 | Marsden, John Christopher | Improvements in or relating to diagnostic/therapeutic agents |
| EP0991427A2 (en) * | 1996-10-28 | 2000-04-12 | Marsden, John Christopher | Improvements in or relating to diagnostic/therapeutic agents |
| WO1998018497A2 (en) * | 1996-10-28 | 1998-05-07 | Nycomed Imaging As | Contrast agents |
-
1998
- 1998-04-22 GB GBGB9808599.6A patent/GB9808599D0/en not_active Ceased
-
1999
- 1999-04-22 EP EP99918133A patent/EP1073473B1/en not_active Expired - Lifetime
- 1999-04-22 WO PCT/GB1999/001221 patent/WO1999053963A1/en not_active Ceased
- 1999-04-22 JP JP2000544366A patent/JP2002512206A/ja not_active Abandoned
- 1999-04-22 KR KR1020007011727A patent/KR20010042915A/ko not_active Withdrawn
- 1999-04-22 CN CN99807622A patent/CN1306442A/zh active Pending
- 1999-04-22 IL IL13914799A patent/IL139147A0/xx unknown
- 1999-04-22 PL PL99343464A patent/PL343464A1/xx unknown
- 1999-04-22 DE DE69937341T patent/DE69937341D1/de not_active Expired - Lifetime
- 1999-04-22 AT AT99918133T patent/ATE375806T1/de not_active IP Right Cessation
- 1999-04-22 BR BR9909822-9A patent/BR9909822A/pt not_active IP Right Cessation
- 1999-04-22 CA CA002329175A patent/CA2329175A1/en not_active Abandoned
- 1999-04-22 HU HU0102878A patent/HUP0102878A3/hu unknown
- 1999-04-22 AU AU36172/99A patent/AU3617299A/en not_active Abandoned
-
2000
- 2000-10-18 ZA ZA200005789A patent/ZA200005789B/xx unknown
- 2000-10-19 NO NO20005250A patent/NO20005250L/no not_active Application Discontinuation
-
2003
- 2003-11-19 US US10/717,196 patent/US20040146462A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002512206A5 (https=) | ||
| RU99110367A (ru) | Улучшенные контрастные агенты или усовершенствования, относящиеся к ним | |
| Kabalnov et al. | Phospholipids as emulsion stabilizers: 2. Phase behavior versus emulsion stability | |
| CN1102045C (zh) | 新的含类脂和稳定剂的组合物 | |
| DE69432358T2 (de) | Gashaltige mikrosphären zur topischen und subkutanen anwendung | |
| EP0788348B1 (en) | Container with multi-phase composition for use in diagnostic and therapeutic applications | |
| US5772984A (en) | Method of ultrasound imaging using microbubble-forming, solid X-ray contrast agents | |
| Tenjarla | Microemulsions: an overview and pharmaceutical applications | |
| Szijjarto et al. | Effects of perfluorocarbon gases on the size and stability characteristics of phospholipid-coated microbubbles: Osmotic effect versus interfacial film stabilization | |
| Miñones Jr et al. | Interactions between membrane sterols and phospholipids in model mammalian and fungi cellular membranes—A Langmuir monolayer study | |
| CN1140255C (zh) | 增白粉 | |
| KR960700757A (ko) | 초음파 콘트라스트 매질로서 유용한 가스 혼합물(gas mixtures useful as ultrasound contrast media) | |
| CZ28999A3 (cs) | Použití kontrastního prostředku | |
| Nakamura et al. | Two-component Langmuir monolayers of single-chain partially fluorinated amphiphiles with dipalmitoylphosphatidylcholine (DPPC) | |
| WO1997029783A1 (en) | Improvements in or relating to contrast agents | |
| JP2004524368A5 (https=) | ||
| JP2002512206A (ja) | 改良された造影剤 | |
| Frangopol et al. | Interactions of some local anesthetics and alcohols with membranes | |
| Li et al. | Multilayer formation on a curved drop surface | |
| CN101827578A (zh) | 反相囊泡组合物 | |
| ES2243350T3 (es) | Agente de contraste liofizable que comprende microburbujas de gas. | |
| Diemel et al. | Effects of cholesterol on surface activity and surface topography of spread surfactant films | |
| Nakagaki et al. | Interaction of differently oriented lipids in monolayer: mixed monolayers of 16-(9-anthroyloxy) palmitic acid with phosphatidylcholine and cholesterol | |
| Courrier et al. | Mixed monolayers made from dipalmitoyl phosphatidylcholine and a fluorinated amphiphile | |
| Cho et al. | Interactions of spread lecithin monolayers with bovine serum albumin in aqueous solution |